X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (36) 36
female (31) 31
humans (31) 31
middle aged (30) 30
aged (29) 29
adult (27) 27
index medicus (25) 25
chemotherapy (22) 22
male (19) 19
cancer (17) 17
prognosis (17) 17
breast cancer (13) 13
care and treatment (12) 12
colorectal cancer (12) 12
disease-free survival (12) 12
survival (12) 12
young adult (12) 12
breast neoplasms - pathology (11) 11
immunohistochemistry (11) 11
research article (11) 11
treatment outcome (11) 11
aged, 80 and over (10) 10
clinical trials (10) 10
metastasis (10) 10
analysis (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cancer research (9) 9
drug therapy (9) 9
hospitals (9) 9
medicine (9) 9
research (9) 9
bevacizumab (8) 8
breast neoplasms - drug therapy (8) 8
genetics (8) 8
patients (8) 8
therapy (8) 8
antineoplastic agents - therapeutic use (7) 7
breast neoplasms - mortality (7) 7
cancer therapies (7) 7
carcinoma (7) 7
chemotherapy, adjuvant (7) 7
genetic aspects (7) 7
medical research (7) 7
medicine & public health (7) 7
neoplasm staging (7) 7
toxicity (7) 7
biomarkers (6) 6
cancer patients (6) 6
gene expression (6) 6
greece (6) 6
health aspects (6) 6
retrospective studies (6) 6
tumors (6) 6
vascular endothelial growth factor (6) 6
adjuvant chemotherapy (5) 5
adjuvant treatment (5) 5
adolescent (5) 5
angiogenesis (5) 5
anthracyclines (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents - adverse effects (5) 5
biomarkers, tumor - genetics (5) 5
drug administration schedule (5) 5
egfr (5) 5
endothelial growth-factor (5) 5
erbb-2 protein (5) 5
follow-up studies (5) 5
kaplan-meier estimate (5) 5
medical prognosis (5) 5
metastases (5) 5
mutation (5) 5
oncology, experimental (5) 5
paclitaxel (5) 5
pathology (5) 5
phase-ii (5) 5
product development (5) 5
radiotherapy (5) 5
risk factors (5) 5
survival rate (5) 5
antineoplastic agents - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
breast neoplasms - genetics (4) 4
carboplatin (4) 4
cisplatin (4) 4
colorectal neoplasms - drug therapy (4) 4
combination (4) 4
dense sequential chemotherapy (4) 4
diagnosis (4) 4
docetaxel (4) 4
drug dosages (4) 4
epidemiology (4) 4
epirubicin (4) 4
gene amplification (4) 4
gene expression regulation, neoplastic (4) 4
genes (4) 4
head and neck cancer (4) 4
head and neck neoplasms - drug therapy (4) 4
multidisciplinary sciences (4) 4
multivariate analysis (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 05/2013, Volume 13, Issue 1, pp. 263 - 263
Background: Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short... 
Metronomic-chemotherapy | Antiangiogenic | Vinorelbine | Cancer | ANGIOGENESIS | CYCLOPHOSPHAMIDE | GROUP HECOG | RECEPTOR | TOXICITY | CHEMOTHERAPY | THERAPY | ONCOLOGY | RESISTANCE | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Vinblastine - analogs & derivatives | Biomarkers, Tumor - metabolism | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Real-Time Polymerase Chain Reaction | Prostatic Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Prostatic Neoplasms - pathology | Enzyme-Linked Immunosorbent Assay | Time-to-Treatment | Administration, Oral | RNA, Messenger - genetics | Translational Medical Research | Liver Neoplasms - drug therapy | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Prostatic Neoplasms - mortality | Breast Neoplasms - pathology | Adolescent | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Drug therapy | Metastasis | Research | Care and treatment | Cancer patients | Chemotherapy | Oncology, Experimental | Fibroblast growth factors | Lung cancer, Non-small cell
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2018, Volume 13, Issue 7, p. e0200302
Several studies support an important role of angiogenesis in breast cancer growth and metastasis. The main objectives of the study were to investigate the... 
CLINICAL ONCOLOGY/COLLEGE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | LYMPHANGIOGENESIS | FACTOR EXPRESSION | VEGF-C | TUMOR ANGIOGENESIS | CARCINOMA | AMERICAN SOCIETY | ENDOTHELIAL GROWTH-FACTOR | Neovascularization, Pathologic - mortality | Neovascularization, Pathologic - diagnosis | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor Receptor-3 - metabolism | Breast - metabolism | Breast Neoplasms - metabolism | Young Adult | Breast Neoplasms - pathology | Vascular Endothelial Growth Factor C - metabolism | Adult | Breast Neoplasms - mortality | Female | Aged | Breast Neoplasms - diagnosis | Neovascularization, Pathologic - metabolism | Breast - pathology | Proteins | Immunohistochemistry | Care and treatment | Cancer patients | Chemotherapy | Patient outcomes | Breast cancer | Vascular endothelial growth factor | Cancer | Health sciences | Laboratories | C protein | Oncology | Paraffin | Kinases | Subgroups | Metastases | Angiogenesis | Signal transduction | Receptors | Epidermal growth factor | Paraffins | Medical research | Parameters | Statistical tests | Gene expression | Patients | ErbB-2 protein | Survival | Vascular endothelial growth factor receptors | Medicine | Pathology | Gene amplification | Hospitals | Anthracycline | Medical prognosis | Biomarkers | Breast | Tumors
Journal Article
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 9/2017, Volume 134, Issue 2, pp. 443 - 451
Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has... 
Neurology | Medicine & Public Health | Non-small cell lung cancer | Oncology | Brain metastases | Breast cancer | Lapatinib | Whole brain radiotherapy | PROGNOSTIC VALUE | EGFR | CHEMOTHERAPY | CLINICAL NEUROLOGY | RADIATION-THERAPY | TEMOZOLOMIDE | CAPECITABINE | ONCOLOGY | GW572016 | GROWTH | TYROSINE KINASE INHIBITOR | CLINICAL ACTIVITY | Brain - diagnostic imaging | Chemoradiotherapy - adverse effects | Follow-Up Studies | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Breast Neoplasms - therapy | Brain Neoplasms - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Treatment Outcome | Brain - radiation effects | Lung Neoplasms - therapy | Disease Progression | Brain - drug effects | Carcinoma, Non-Small-Cell Lung - therapy | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Brain Neoplasms - therapy | Quinazolines - adverse effects | Aged | Tyrosine | Brain | Care and treatment | Oncology, Experimental | Clinical trials | Lung cancer, Small cell | Metastasis | Research | Lung cancer, Non-small cell | Antineoplastic agents | Radiotherapy | Antimitotic agents | Analysis | Cancer | Dexamethasone | Epidermal growth factor receptors | Toxicity | Lung cancer | Non-small cell lung carcinoma | Radiation therapy | ErbB-2 protein | Metastases | Magnetic resonance imaging | Cell lines | Protein-tyrosine kinase
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2012, Volume 132, Issue 2, pp. 609 - 619
Journal Article
Journal Article